[Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (AMR Alliance Japan, December 22, 2021)
date : 12/22/2021
Tags: AMR
![[Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (AMR Alliance Japan, December 22, 2021)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-case04-top_ENG.jpg)
As part of the Alliance’s project to promote antimicrobial steward among medical professionals, AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) has begun publishing case studies from various experts related to antimicrobial resistance.
Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital) reports a case titled “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”.
Case study 04
Dr. Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital)
“The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”
For further information, please see the case study below.
Case study 01
Dr. Keiji Okinaka (Director of Infection Control and Prevention Section, National Cancer Center Hospital East / Department of General Internal Medicine, National Cancer Center Hospital East /Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
“A disseminated filamentous fungal infection that broke through echinocandin antifungal treatment”
Top Research & Recommendations Posts
- [Policy Recommendations] Achieving a Sustainable Society of Health and Longevity Through the Integration of Environment and Healthcare-Incorporating a Planetary Health Perspective into the 3rd Phase of The Healthcare Policy-(December 20, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Policy Recommendations on Strengthening CKD Strategies for Workers: The Importance of Providing Early Detection, Intervention, and Support Through Screenings and Medical Visits (October 28, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Policy Recommendations] Cancer Control Project “Policy Recommendations on Addressing Regional Disparities in Breast Cancer Care” (January 31, 2025)
Featured Posts
-
2025-01-22
[Registration Closed] HGPI Salon 2025 “Looking Ahead to the Future of Japan’s Social Security System” Session 1: Improving Productivity through the Streamlining of Healthcare and Long-Term Care Services and the Utilization of ICT (February 14, 2025)
-
2025-01-31
[Research Report] Comparative Research Group on Local Regulations for Dementia Presents Final Report, “Toward Dementia Regulations for an Inclusive Society” (December 27, 2024)
-
2025-02-01
[Announcement] Announcement of the 1st Kiyoshi Kurokawa Award Recipient
-
2025-02-07
[Publication Report] The Child Health Project Publishes Family Mental Health Booklet “Learning and Practicing at Home – Stress Management for Children with Intellectual Disabilities” (February 3, 2025)